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T imothy Stange was 12 years old, growing up in Wisconsin, when his parents took him to a 
doctor to treat his Tourette’s syndrome, an illness marked by sudden involuntary tics and 
sounds. 
 
His doctor, a neurologist who specialized in treating children, prescribed Risperdal. The drug is 
an antipsychotic medication that has never been approved by the U.S. Food and Drug 
Administration for treating Tourette’s. 
 
Instead, the prescription for Stange is deemed an off-label use, where a doctor believes a drug 
may still be useful, even though the FDA has not found evidence that the medication is safe or 
effective for treating that illness. 
 
For Stange, the drug did not work as planned. 
 
A year later he began Risperdal, Stange’s mother took him to a pediatrician for stabbing pains 
around his left chest. Two years after that, Timothy had grown female-like breasts. 
 
Classmates noticed. Timothy recounted being bullied. Six years after he first took Risperdal, the 
teenager needed a plastic surgeon to give him a double mastectomy to remove the breasts, 
leaving him with scars on his chest. 
 
He is far from alone. 
 
Roughly 16 to 20 percent of children and adolescents in the United States suffer from mental 
health illness, ranging from anxiety to depression to attention-deficit disorders and other 
behavioral issues, according to federal government statistics. 
 
To treat these illnesses, psychiatrists and other mental health professionals deploy a range of 
therapies like counseling, classroom support, accommodations -- and drugs. 
 
About 6 percent of all youths age 12 to 19-years-old take some kind of drug for treating a mental 
health issue, according to one of the most recent studies by the US Centers for Disease Control a 
nd Prevention, echoing work by other researchers. 
 
Among the more common drugs are antipsychotic medications. They are designed to help 
those with illnesses like schizophrenia, bipolar disorder and aggressive behaviors stemming 
from autism. But an expansive study several years ago estimates that two-thirds of all 
antipsychotic medications prescribed for children and adolescents in the United States is 
off-label. 
 
That translates into one in every 100 adolescents in America is on an antipsychotic medication 
like Risperdal. 
 
Even more youths are on different medications for treating mental illness -- like antidepressants 
and, for attention-deficit disorders, stimulants like Adderall. 
 
When prescriptions to those youths are for antipsychotic and antidepressant medications, there 
is a good chance it is off-label, with no FDA approvals. This pattern has raised concerns in the 
medical profession and among patients and their families. 
 
Stange is among more than 13,600 who have sued Jannsen Pharmaceuticals, a subsidiary of 
the drug giant Johnson & Johnson, for the physical damage he suffered, alleging the company 
had hidden and downplayed evidence of ill side effects. Stange’s doctor said that while he was 
aware that Risperdal could cause a boy to grow breasts, he was under the impression this was 
rare. 
 
After winning before a jury and later appeals altering the judgement, Stange settled out of court 
for an undisclosed sum. Others have recently won amounts from $2.5 million to $70 million. 
 
Johnson & Johnson, and its subsidiary Janssen, faced an investigation by the U.S. Justice 
Department for promoting off-label uses of Risperdal and allegedly paying kickbacks to 
physicians. The companies settled the probe for $2.2 billion. The probe included allegations 
regarding Risperdal and two other drugs, the antipsychotic Invega and the vascular medicine 
Natrecor. 
 
Other parents and patients have sued different drug makers for promoting off-label treatments 
for mental health illnesses, like depression and anxiety, alleged they suffered mental damage 
and physical harm. Some surviving family members allege these prescriptions spurred youths to 
kill themselves. 
 
H OW OFF-LABEL WORKS 
 
To understand how off-label prescriptions work, consider the case of Clinton Harper. 
 
Clinton was four years old when he was diagnosed with autism in 1994. His mother recalled that 
he was a handful. 
 
“My son would not sleep,” his mother Teresa Harper said. “He would stay up and he was like the 
Energizer rabbit. He’d never stop. He was just going and going and going and going. We had to 
slow him down.” 
 
By age six he was prescribed Risperdal, which at the time was not approved by the FDA for any 
use in children. 
 
A doctor, Jan Mathisen, prescribed Risperdal to manage his symptoms. 
 
Mathiesen later testified that he had no record of telling his mother that this was off-label -- that 
there is no FDA-approved use of this drug for this treatment. 
 
The FDA approves drugs and also oversees the language put on the labels of pharmaceuticals. 
These labels tell doctors and patients uses and risks of a drug. The approved uses mean there 
is a body of academic work and studies about the effectiveness and safety of the medication. 
 
But there are times when doctors may choose to go beyond the FDA-designated uses. 
 
Congress has long permitted wide leeway for doctors to decide when is best for prescribing 
drugs for off-label uses. 
 
D octors are not required to tell patients or -- in the case of youths, their parents -- that the 
medications are off-label. 
 
For psychiatrists treating youths, this may be because standard medications are not working. A 
drug that helps adults -- even though it has not been tested on children for safety, side effects 
and effectiveness -- may be an alternative. 
 
“There are times where it is not a totally unreasonable thing to do,” said Dr. Ryan S. Sultan, a 
Columbia University professor and psychiatrist who has examined the use of antipsychotic 
medications for children. 
 
Sultan said among the times when off-label uses might make sense is for children “getting 
kicked out of school regularly. They’re getting suspended. You’ve tried behavioral treatment. 
You’ve tried individual psychotherapy. You’ve tried parent management and you’ve tried the 
medications that are more likely to be helpful.” 
 
While Clinton Harper was not on the verge of getting kicked out of school, the drug worked -- at l 
east for treating the manifestations of his autism. 
 
But along with the drug came side effects -- something the doctor has no record of ever warning 
the mother or son about, though they are listed on packaging that comes with the prescription. 
In just one year, according to his mother, Clinton went from being a normal-sized kid to being 
“obsessed with food.” When he became too big for Teresa so manage, she felt she needed to 
put him in a group home. 
 
“My child went from a baby to a grown man in one year,” Teresa Harper said. “How do you 
prepare for that? You don’t. You can’t. You talk about some pain.” 
 
“If I had to do it all over again, I would not have put him on Risperdal? No,” she said. “Because it 
changed my son’s whole life.” 
 
In 2016 doctors diagnosed Clinton with gynecomastia, the condition that causes the 
enlargement of male breasts. 
 
Cases like Harper’s are not unusual. 
 
Sultan published a study in 2019 examining prescriptions for treating attention deficit disorder. 
Medical manuals outline that the standard medications are stimulants. Sultan found 2.6 percent 
of those with attention deficit diagnoses were instead on antipsychotic medications, and for 
about half of them, stimulants were never tried. 
 
“One of the arguments is this should never ever ever ever be used. And anyone who is a decent 
practicing clinician would say that’s ridiculous,” said Sultan. “It should be used as a sort-of last 
r esort.” 
 
W IDE RANGE OF DRUGS PRESCRIBED FOR MENTAL HEALTH 
 
Antipsychotic medications are not the only type of medication prescribed off-label to children 
suffering from mental illness, and are just one category of the array of drugs that are used for 
mental health treatment. 
 
The two most common kinds of medications are antidepressants -- like Lexapro and Zoloft -- 
and attention disorder drugs -- like Adderall and Ritalin. A little more than 3 percent of youths 
are on each category of these pharmaceuticals. 
 
Antipsychotics -- such as Risperdal and Zyprexa are the third most commonly prescribed type 
of medication. About 1 percent of youths are on these. 
 
L ess commonly used categories of drugs are anti-anxiety medications; sedatives; hypnotics like 
Ambien; and drugs designed to prevent mania, like Lithium. 
 
The use of these medications is prevalent not just for teenagers but for younger children. 
When it comes to using these drugs off-label for children and adolescents, the practice is 
prevalent not only prevalent in the U.S, but also in other Western countries. Exact numbers are 
hard to come by, but by analyzing a range of data troves, researchers have documented 
widespread off-label use, and it is more prevalent in some categories of drugs. 
 
A 2016 study in the European Child & Adolescent Psychiatry journal found that the rates of 
off-label prescribing worldwide are as high as 65 percent in pediatric hospitals. 
 
The same journal, in a separate study, found drugs for mental health illnesses were prescribed 
off-label at a rate of 96.4 percent at Danish outpatient clinics treating children and adolescents. 
It examined healthcare insurance claims that showed an off-label prescription rate for youths of 
70 percent in the United States. 
 
A study comparing Germany, the Netherlands and the United States showed that 
antidepressant, stimulant and antipsychotic medication use were 1.5 to 3 times higher in the 
United States compared to the other two nations. 
 
The authors wrote that this indicates American families are more likely to favor medications to 
address mental health problems than families in Germany and the Netherlands. 
 
O ff-label prescribing of antipsychotic medication 
 
Antipsychotic medications began entering the marketplace in the 1950s are mainly for treating 
conditions such as bipolar disorder and schizophrenia. 
 
A new wave of antipsychotics began entering the market in the 1990s and early 2000s that r 
educed side effects like tremors, tics and Parkinsons-like tremors. 
 
Today, bipolar disorder and schizophrenia among older youths and adults are commonly treated 
with drugs like Risperdal and Zyprexa, which are FDA-approved on-label uses. 
 
Throughout the last two decades, antipsychotics have undergone various label changes to 
better inform patients about the potential risks of both on and off-label use. 
 
As these newer antipsychotics began receiving FDA approvals for bipolar, schizophrenia and 
irritability associated with autism, new age groups were also approved. 
 
As such, the market for these drugs has exploded. In 2011, antipsychotic sales t otaled $18.2 
billion, up $2.1 billion from the prior year. From 2013 to 2014, sales of Abilify, a newer 
antipsychotic, increased from $6.5 billion to $7.8 billion. 
 
Many of the children and teenagers taking these medications are not suffering from 
FDA-approved conditions like schizophrenia. Instead they are taking these for off-label needs. 
 
Between 1993 and 2010, one study found more than two-thirds of outpatient visits for those 
ages 4 to 18, where the result was an antipsychotic prescription, received the medication for an 
off-label use. 
 
As many as 31 percent of children treated with antipsychotic medication have been diagnosed 
with attention disorders, while 34.5 percent of young adults treated with antipsychotics have 
been diagnosed with depression, according to another study. 
 
Antipsychotics work by blocking dopamine, one of the body’s naturally produced chemicals to 
signal pleasure. 
 
The medications “destroy your capacity to detect the pleasurable signal in the world,” said 
William Wirshing, a psychiatrist at the University of California in Los Angeles. 
 
No antipsychotics have been approved for treating depression or attention disorders by the FDA 
for children. 
 
The newer generation of antipsychotics have reduced some adverse events, such as 
involuntary movements, associated with the earlier versions of the drugs. 
 
But the new pharmaceuticals have other side effects that the older drugs do not have -- like 
rapid weight gain and diabetes. 
 
A study in Europe in 2019 found elevated adverse events for youths prescribed antipsychotic 
medications. While many patients benefited from the medications, 12 percent experienced an 
adverse event. The researchers urged doctors to closely monitor side effects. 
 
Thousands of adolescent boys like Timothy Stange and Clinton Harper who have been 
prescribed Risperdal, one of the newer drugs, have suffered from growing breasts, a disorder 
known as gynecomastia. 
 
In 2003, Nicholas Murray was 9 years old when he was prescribed Risperdal off-label to treat 
sleeping troubles attributed to his autism. He stayed on the medication until 2008, and was later 
diagnosed with gynecomastia. 
 
Murray sued Jannsen Pharmaceuticals, a subsidiary of the drug manufacturer Johnson & 
Johnson, and a jury awarded him a $1.7 million in 2015, which was later reduced to $680,000. 
 
Last October, a Philadelphia jury ruled that both Janssen and its parent company would pay 
Murray $8 billion in punitive damages. 
Murray is far from alone. Johnson & Johnson’s most recent SEC filings from October show that 
at least 13,600 others have sued the company over its antipsychotic drug Risperdal. 
 
P harma response to off-label uses, cases 
 
Pharmaceutical companies make clear that there are countless patients who have benefitted 
from medications to treat the mentally ill, including when doctors prescribe drugs off label. 
 
But drug giants such as Johnson & Johnson, AstraZeneca and Eli Lilly have denied wrongdoing 
when faced with allegations regarding life-changing consequences from their antipsychotics. 
 
In court they have argued that there is little evidence the drugs have caused these ill effects, 
and instead have blamed a patient’s unhealthy diet, lifestyle or other medications. 
 
In Murray’s case, Janssen denied “any significant risk of gynecomastia from the use of 
Risperdal.” 
 
Under FDA regulations, drug companies are limited from promoting off-label uses. They cannot 
promote off-label drugs directly to patients, but they can distribute studies to doctors that show 
an off-label use that may be helpful. 
 
Yet, several pharmaceutical companies have been accused of off-label marketing in recent 
years, and even published brochures and professional journal ads. 
 
In one of the largest health care fraud settlements in U.S. history, Johnson & Johnson reached 
a massive settlement with the Department of Justice in 2013. 
 
The company paid more than $2.2 billion “to resolve criminal and civil liability arising from 
allegations relating to the prescription drugs Ripserdal, Invega and Natrecor.” Both Risperdal 
and Invega are antipsychotic drugs. 
 
“J&J’s promotion of Risperdal for unapproved uses threatened the most vulnerable populations 
of our society – children, the elderly and those with developmental disabilities,” said U.S. 
Attorney for the Eastern District of Pennsylvania Zane Memeger. “This historic settlement 
sends the message that drug manufacturers who place profits over patient care will face severe 
criminal and civil penalties.” 
 
In 2009, Zyprexa drug manufacturer Eli Lilly and Company also entered a global resolution with 
the Justice Department and pled guilty “to resolve criminal and civil allegations that it promoted 
its antipsychotic drug Zyprexa for uses not approved by the FDA.” 
 
Eli Lilly paid fines of a little more than $1.4 billion. 
Astrazeneca was forced to pay $520 million in fines in 2010 for illegally marketing its 
antipsychotic drug Seroquel, including to youths, according to the Justice Department. 
 
Combined, the manufacturers of three of the most commonly prescribed antipsychotics - 
AstraZeneca, Eli Lilly and Johnson and Johnson - have paid more than $4 billion in fines in the 
last decade to settle off-label marketing claims. That price tag is nearly the equivalent of the net 
worth of the New York Yankees, the second most valuable sports franchise in the country. 
 
N ot Just Antipsychotics: Anti Depressants And Off Label Incidents 
 
Antipsychotics are not the only drugs prescribed off-label for mental illness in youths that have 
been the subject of litigation. 
 
In Massachusetts, Delana Kiossovski was looking to treat her daughter’s depression. Dr. 
Stephen Barnett put the 12-year-old on Celexa in July 2001. 
 
Her daughter then attemped suicide twice. Her family, in court, asserted the drug was to blame. 
 
Kiossovski joined with another patient in 2014 to sue the pharmaceutical manufacturer Forest 
Labs, charging that Celexa and Lexapro, another antidepressant, were promoted for off-label 
use in children. 
 
The evidence in cases like the one for Kiossovski “strongly suggests that Forest engaged in a 
comprehensive off-label marketing scheme from 1998 through 2009 aimed at fraudulently 
inducing doctors to write pediatric prescriptions of Celexa and Lexapro,” US Appeals Court 
Judge William J. Kayatta Jr., wrote in January 2019. This happened, he wrote, even though 
“Forest had insufficient reason to think that these drugs were effective for the treatment of 
depression in children and adolescents.” 
 
Celexa was also the subject of another lawsuit against Forest Labs in 2014. 
 
Woody Wilcox was 12 when he was prescribed Celexa off-label by an adolescent psychiatrist, 
David Ritvo. Ritvo stated that Wilcox exhibited signs of obsessive-compulsive disorder , 
attention deficit disorder, depression and anxiety. To treat these, he prescribed Celexa. 
 
Wilcox the suffered from violent nightmares, maniacal behavior and symptoms of bipolar 
disorder. 
 
Another psychiatrist, Peter Breggin, said this could have been a result of Celexa. 
 
W ilcox’s father, Scott, sued Forest Labs on the grounds that they made “fraudulent, false, 
unlawful and misleading representations that [Celexa] was safe and effective for minor children.” 
Forest Labs countered that TK 
 
The case was dismissed by a judge. 
 
Eleven-year-old Trevor Blain, a Kansas resident, suffered from fear and anxiety about attending 
school. His parents had also divorced and his mom, Pamela Blain, became increasingly 
concerned about Trevor’s mental stability. 
 
She took him to a pediatrician, who would end up determining that Trevor had separation 
anxiety and suggested Pamela take him to a psychiatrist. 
 
Blain followed the doctor’s advice and went to see the psychiatrist, who would diagnose Trevor 
with depression in addition to the separation anxiety. As a result, in October 2000, Trevor began 
taking between 10mg and 20mg of Paxil, a popular antidepressant, daily. 
 
Shortly thereafter, Trevor would begin exhibiting explosive outbursts, restlessness, insomnia 
and emotional detachment. He would end up committing suicide. 
 
Blain sued Paxil’s manufacturer, SmithKline Beecham, in 2007. She claimed in the lawsuit that 
“despite its specific knowledge of Paxil's association with the increased risk of suicidality in 
pediatric patients, the defendant GlaxoSmithKline ("GSK") failed to warn doctors, the medical 
community and the public of this danger.” 
 
The case continued until 2 008, when United States District Judge Monti L. Belot denied Blain’s 
motion for reconsideration of her case. 
 
S elf worth 
 
The dangers of off-label prescriptions on children and adolescents isn’t limited to physical side 
effects. 
 
There is the bullying, as experienced by Timothy Stange, the boy who grew breasts after being 
prescribed Risperdal for Tourette’s syndrome at age 12. 
 
But prescribing medications for mental health can affect children’s sense of self, said Tony 
Stanton, a child psychiatrist in Bainbridge Island near Seattle. 
 
“Long-term, this has some really unfortunate results,” he said, “For one thing, it tells the child 
that there’s something organically wrong with them, that their brain isn’t right. And they kind of 
have that as a legacy.” 
 
“One of the things that it does is it takes away their agency -- their ability to actually make 
changes in their own lives,” he sa
 
— THE END — 
